Xagenic scores Series B funds

Toronto-based molecular diagnostics company Xagenic has secured C$15 million in Series B funding. The investors included Domain Associates, CTI Life Sciences, BDC Capital and the Ontario Capital Growth Corporation.

Milestone Pharmaceuticals picks up $17 mln

Canada-based Milestone Pharmaceuticals, a drug developer focused on cardiovascular diseases, has raised $17 million in Series B funding. Domain Associates led the round with participation from other investors that included Fonds de solidarité FTQ, Pappas Ventures, BDC Capital, GO Capital and iNovia Capital. In conjunction with the funding, Domain’s Debra Liebert has been added to Milestone’s board of directors.

307 Views

VC-backed Glaukos Corp files for IPO

Laguna Hills, California-based Glaukos Corporation, a developer of treatments for glaucoma, has filed for an IPO. The number of shares that will be sold as well as the IPO’s pricing terms have yet to be set. The company plans on trading the stock on the NYSE under the ticker symbol “GKOS.” J.P. Morgan, BofA Merrill Lynch and Goldman, Sachs & Co are serving as the lead underwriters. Glaukos’ backers include OrbiMed Advisors, Frazier Healthcare Ventures, InterWest Partners, Domain Associates, Fjord Ventures, Montreaux Equity Partners and Versant Ventures

VC-backed aTyr Pharma rolls out IPO

San Diego-based biotherapeutics company aTyr Pharma Inc has debuted its IPO after pricing its 5.36 million shares at $14 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “LIFE.” J.P. Morgan Securities LLC and Citigroup Global Markets are serving as the lead underwriters. The company’s backers include Alta Partners, Cardinal Partners, Domain Associates, Polaris Partners, Sofinnova Ventures, T. Rowe Price Associates Inc, Federated Investors Inc, Deerfield, Rock Springs Capital Management, EcoR1 Capital and Sphera Global Healthcare.

VC-backed aTyr files for IPO

San Diego-based biotherapeutics company aTyr Pharma Inc has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. The company plans on trading its stock on the NASDAQ under the ticker symbol “LIFE.” J.P. Morgan Securities LLC and Citigroup Global Markets Inc will serve as the lead underwriters. The company’s backers include Alta Partners, Cardinal Partners, Domain Associates, Polaris Partners, Sofinnova Ventures, T. Rowe Price Associates Inc, Federated Investors Inc, Deerfield, Rock Springs Capital Management, EcoR1 Capital and Sphera Global Healthcare.

161 Views

Obalon Therapeutics nabs $30 mln

San Diego-based Obalon Therapeutics, a developer of gastric balloon technology for weight loss therapy, has received $20 million in Series D funding and a $10 million loan from Square 1 Bank. The Series D investors included Axon Ventures, Mirae Asset Venture Investment, Striker Asia Opportunities Fund, Domain Associates, InterWest Partners and Okapi Venture Capital.

106 Views

CoLucid Pharmaceuticals nabs $37.1 mln

Durham, North Carolina-based CoLucid Pharmaceuticals, which develops oral lasmiditan that treats migraine headaches, has raised $37.1 million in Series C funding. TVM Capital Life Science led the round with participation from other investors Novo Ventures, Auriga Partners, Pappas Ventures, Domain Associates, Care Capital, Triathlon Medical Ventures and Pearl Street Ventures. Also, Dr. Luc Marengere of TVM Capital Life Science and Dr. Martin Edwards of Novo Ventures have been added to CoLucid’s board of directors.

143 Views

BioNano Genomics scores $53 mln Series C

San Diego-based BioNano Genomics, a provider of genome mapping, has closed $53 million in Series C financing. Legend Capital and Novartis Venture Fund led the round with participation from Federated Kaufmann Fund, Monashee Investment Management, Domain Associates, Battelle Ventures and Gund Investment Corp. In conjunction with the funding, Dr. Darren Cai of Legend Capital and Dr. Campbell Murray of Novartis Venture Fund have been added to BioNano’s board of directors.

159 Views

Fractyl garners $40 mln Series C

Fractyl Laboratories said Thursday that it has secured $40 million in Series C funding. Mithril led the round with participation from General Catalyst, Bessemer Venture Partners and Domain Associates. In conjunction with the funding, Ajay Royan, Mithril’s co-founder and managing general partner, has been added to the company’s board of directors. Based in Waltham, Mass., Fractyl is a developer of a device-based endoscopic procedure to treat Type 2 diabetes.

133 Views

Epic Sciences picks up $30 mln Series C

Epic Sciences said Wednesday that it has secured $30 million in Series C financing. The investors included RusnanoMedInvest, Arcus Ventures, Domain Associates, Roche Venture Fund and Pfizer Venture Investments. Based in San Diego, Calif., Epic is a biotech firm focused on cancer diagnostics.

VC-backed Otonomy files for IPO

Otonomy said Monday that it has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. J.P. Morgan Securities and BofA Merrill Lynch are serving as the lead underwriters. Based in San Diego, Calif., Otonomy is a biopharmaceutical company that develops treatments for ear disorders and diseases. Its backers include Perceptive Advisors, Federated Kaufmann Funds, OrbiMed Advisors, Novo Ventures, TPG Biotech, Avalon Ventures, Domain Associates, RiverVest Venture Partners, Aperture Venture Partners and Osage University Partners.

05062014feverchart

Gains in venture performance lift University of California portfolio: VCJ

A maturing slice of the University of California’s venture portfolio is benefiting from the venture industry’s performance gains of the past year, according to affiliate magazine Venture Capital Journal. The majority of the 20 funds the university holds with vintages of 2003 to 2006 advanced smartly in 2013 and 17 now have positive IRRs.

174 Views

VC-backed ProteinSimple files for IPO

ProteinSimple has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. The company plans on listing the stock on the NASDAQ under the ticker symbol “PRTN.” JP Morgan and BofA Merill Lynch will serve as lead underwriters. Based in Santa Clara, Calif., ProteinSimple is a provider of protein analysis. Its backers include Essex Woodlands Health Ventures, Novo AS and Domain Associates.

Otonomy scores $49 mln Series D funds

Otonomy said Wednesday that it has closed $49 million in Series D funding. The investors included Perceptive Advisors, Federated Kaufmann Funds, OrbiMed Advisors, Novo Ventures, TPG Biotech, Avalon Ventures, Domain Associates, RiverVest Venture Partners, Aperture Venture Partners and Osage University Partners. Based in San Diego, Calif., Otonomy is a biopharmaceutical company that develops treatments for ear disorders and diseases.

Sequent Medical rakes in $20 mln

Sequent Medical said Tuesday that it has received $20 million in Series D financing. Previous backer Delphi Ventures led the round with participation from Domain Associates, US Venture Partners and Versant Ventures. Headquartered in Aliso Viejo, Calif., Sequent Medical is a medical-device company focused on catheter-based neurovascular technologies.

VC-backed Syndax Pharmaceuticals files for IPO

Syndax Pharmaceuticals has filed for an IPO. The number of shares that will be offered as well as the stock’s pricing terms have yet to be set. Deutsche Bank Securities and Jefferies are serving as lead underwriters. Headquartered in Waltham, Mass., Syndax is a Syndax Pharmaceuticals is a developer of epigenetic therapies for treatment-resistant cancers. Its backers include Domain Associates, MPM Capital, Forward Ventures, Pappas Ventures and Avalon Ventures.

VC-backed Achaogen debuts IPO

Achaogen has launched its IPO after pricing its 6 million shares at $12 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol “AKAO.” Credit Suisse Securities and Cowen and Company are the lead underwriters. Based in South San Francisco, Achaogen is a biopharmaceutical company focused on developing antibiotics to treat bacterial infections. Its backers include 5AM Ventures, ARCH Venture Partners, Venrock, Versant Ventures, Frazier Healthcare Ventures, Domain Associates and Alta Partners.

PE HUB Community

Join the 12519 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget